Novartis (Mid-Stage Clinical Product Portfolio) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Novartis (Mid-Stage Clinical Product Portfolio) General Information

Description

Novel products for the treatment of diseases with unmet medical need. It includes human monoclonal antibody to improve bone density in osteogenesis imperfecta (OI), an orally active aromatase inhibitor for the treatment of obese men with hypogonadotrophic hypogonadism and a orally active p38 MAP kinase inhibitor for the treatment and supportive care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Drug Discovery
Acquirer
Primary Office
  • Basel
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (Mid-Stage Clinical Product Portfolio) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (Mid-Stage Clinical Product Portfolio)‘s full profile, request access.

Request a free trial

Novartis (Mid-Stage Clinical Product Portfolio) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (Mid-Stage Clinical Product Portfolio)‘s full profile, request access.

Request a free trial